WASHINGTON, D.C. — Patients For Affordable Drugs Now kicks off a seven-figure campaign today that will highlight patients calling on members of Congress to keep their promises and support H.R. 3, a comprehensive package of drug pricing reforms that includes allowing Medicare to negotiate lower prices for all Americans. The campaign is launching in 42 House districts across 22 states and in D.C., deploying TV ads, digital ads, and grassroots advocacy, in which patients will contact their members of Congress directly. 

“This campaign is a clear message to Congress: If you stand with patients in support of Medicare negotiation to lower prescription drug prices, we have your back,” said David Mitchell, a cancer patient and founder of Patients For Affordable Drugs Now. “This issue is a political winner, and we will do everything in our power to ensure members who stand up to Big Pharma get the credit they deserve.”

”We need H.R. 3 to restore balance so Americans get the innovation we need at prices we can afford. As the president said, ‘Let’s do it now,’” Mitchell said.

Watch the ad launching the campaign here

“I was diagnosed with type 1 diabetes at 15 years old. Because insulin is so expensive, I’ve had to skip and ration my doses. My wife has had to skip meals so that we could afford the insulin that I needed to survive,” Marcus LaCour, a Cincinnati husband, father, minister, and drug affordability advocate says in the ad playing on TV and digital platforms. “No family should have to make that decision. Millions of Americans need help.”

This campaign comes on the heels of Big Pharma’s recent attack ads loaded with lies about H.R. 3. Big Pharma is doing everything it can to fight againstlower drug prices, running ads across 43 House districts with false claims that any curbs on the industry’s unilateral pricing power will cause important innovation to grind to a halt.

H.R. 3, the Elijah E. Cummings Lower Drugs Costs Now Act, was recently reintroduced in the House of Representatives. The chamber passed the bill in the 116th Congress. It will lower prices, rein in price gouging, and reduce out-of-pocket costs by restoring balance to the U.S. drug pricing system to ensure both innovation and affordability.

Districts where campaign is launching: